Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority …
J Halton, LR Brandão, M Luciani, L Bomgaars… - The Lancet …, 2021 - thelancet.com
Background Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the
limitations of standard of care in children with venous thromboembolism. The aims of this …
limitations of standard of care in children with venous thromboembolism. The aims of this …
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority …
DIVERSITY Trial Investigators - The Lancet …, 2021 - providence.elsevierpure.com
Background: Dabigatran etexilate is a direct oral anticoagulant with potential to overcome
the limitations of standard of care in children with venous thromboembolism. The aims of this …
the limitations of standard of care in children with venous thromboembolism. The aims of this …
[PDF][PDF] Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non …
J Halton, LR Brandão, M Luciani, L Bomgaars… - 2020 - dial.uclouvain.be
Background Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the
limitations of standard of care in children with venous thromboembolism. The aims of this …
limitations of standard of care in children with venous thromboembolism. The aims of this …
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority …
J Halton, LR Brandão, M Luciani… - THE LANCET …, 2020 - iris.uniroma1.it
Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations
of standard of care in children with venous thromboembolism. The aims of this clinical trial …
of standard of care in children with venous thromboembolism. The aims of this clinical trial …
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority …
J Halton, LR Brandão, M Luciani, L Bomgaars… - The Lancet …, 2021 - iro.uiowa.edu
Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations
of standard of care in children with venous thromboembolism. The aims of this clinical trial …
of standard of care in children with venous thromboembolism. The aims of this clinical trial …
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority …
J Halton, LR Brandão, M Luciani… - The Lancet …, 2020 - europepmc.org
Background Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the
limitations of standard of care in children with venous thromboembolism. The aims of this …
limitations of standard of care in children with venous thromboembolism. The aims of this …
[PDF][PDF] Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non …
J Halton, LR Brandão, M Luciani, L Bomgaars… - 2020 - researchgate.net
Background Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the
limitations of standard of care in children with venous thromboembolism. The aims of this …
limitations of standard of care in children with venous thromboembolism. The aims of this …
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority …
J Halton, LR Brandão, M Luciani… - Lancet …, 2021 - digitalcommons.providence.org
BACKGROUND: Dabigatran etexilate is a direct oral anticoagulant with potential to
overcome the limitations of standard of care in children with venous thromboembolism. The …
overcome the limitations of standard of care in children with venous thromboembolism. The …
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority …
J Halton, LR Brandão, M Luciani… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the
limitations of standard of care in children with venous thromboembolism. The aims of this …
limitations of standard of care in children with venous thromboembolism. The aims of this …
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority …
J Halton, LR Brandão, M Luciani… - The Lancet …, 2021 - scholarship.miami.edu
Abstract Acute Disease Dabigatran-adverse effects Venous Thromboembolism-mortality
Dabigatran-administration & dosage Anticoagulants-administration & dosage …
Dabigatran-administration & dosage Anticoagulants-administration & dosage …